About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 4NCT04555694

Comparing Treatment of Dry Eye With Intracanalicular Dexamethasone, Restasis, and/or Lotemax

This 6 month study seeks to compare the use of Intracanalicular Dexamethasone in conjunction with Restasis (cyclosporine ophthalmic emulsion) for the treatment of signs and symptoms of dry eye disease...

Lead sponsor: Thomas Chester, OD•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Thomas Chester, OD

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•18 years of age or older
•Signs and symptoms of Dry Eye Disease
•Consent to treat with topical immunomodulator
•Willing and able to comply with clinic visits and study related procedures
•Willing and able to sign the informed consent form

Exclusion Criteria

•Patients under the age of 18.
•Pregnancy (must be ruled out in women of child-bearing age with pregnancy test)
•Active infectious systemic disease
•Active infectious ocular or extraocular disease
•Altered nasolacrimal flow of either acquired, induced, or congenital origin
•Hypersensitivity to dexamethasone
•Patients who have been on topical immunomodulating agents in the previous 3 months to their baseline visit
•Patient being treated with either topical, oral, or intravenous immunosuppressive agents, immunomodulating agents, or steroid (including NSAIDS)
•Patients with severe disease that warrants critical attention, deemed unsafe for the study by the investigator

Related studies

RECRUITINGPhase 2

Dose-Finding Study of HUC1-394 in Participants With Dry Eye Disease

NCT07656688 · Dry Eye Disease (DED)

Impact of GLP-1 Receptor Agonists on Dry Eye Disease in Patients With Type 2 Diabetes Mellitus and Obesity

NCT07605572 · Dry Eye Disease (DED), Diabete Mellitus, and more

Comparative Assessment of Lipid Layer Thickness Measurements

NCT07579130 · Dry Eye

Real-World Assessment of VEVYE® for Short-Term Symptom and Sign Improvement of Dry Eye Disease in a Neuro-Ophthalmology Clinic: A 6-Month Prospective Observational Study

NCT07566975 · Dry Eye

Therapeutic Efficacy and Safety of Non-Invasive RF Treatment in Refractory MGD

NCT06220474 · Dry Eye Syndromes, Meibomian Gland Dysfunction

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 11, 2023Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE4

Enrollment30

Start dateOct 2020

Last updatedOct 11, 2023

Condition

Locations shown

Cleveland Eye Clinic

Brecksville, Ohio

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 11, 2023Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions